NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Mar 17, 2020

Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates

Mar 16, 2020

Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Feb 26, 2020

Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™

Feb 12, 2020

Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa

Jan 21, 2020

Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids

Jan 15, 2020

Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Jan 13, 2020

Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dec 24, 2019

Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants

Dec 20, 2019

Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA

Dec 20, 2019
RSS
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...31

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use